Newsroom

Newsroom

Plasma first: Accelerating lung cancer diagnosis through liquid biopsy

Literature
Read More

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Literature
Read More

NeoGenomics will be exhibiting at the 2022 ASCO Annual Meeting from June 4 – 6

Blog
Read More

Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay

Literature
Read More

NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory

Press Release
Read More

NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences

Press Release
Read More

NeoGenomics Appoints Lynn Tetrault Interim CEO

Press Release
Read More

NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR® MRD and InVisionFirst®-Lung Tests at the 2022 ASCO Annual Meeting

Press Release
Read More

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients